Amplia Therapeutics Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
9
- Stock Symbol
-
ATX
- Investments
-
1
- Share Price
-
$0.11
- (As of Friday Closing)
Amplia Therapeutics General Information
Description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
Contact Information
Website
www.ampliatx.comCorporate Office
- Level 17
- 350 Queen Street
- Melbourne, Victoria 3000
- Australia
Corporate Office
- Level 17
- 350 Queen Street
- Melbourne, Victoria 3000
- Australia
Amplia Therapeutics Timeline
Amplia Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.11 | $0.11 | $0.04 - $0.12 | $30.5M | 275M | 1.05M |
Amplia Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 10,027 | 7,535 | 6,386 | 11,699 |
| EBITDA | (2,948) | (4,245) | (2,687) | |
| Net Income | (2,961) | (4,266) | (2,690) | |
| Total Assets | 9,675 | 12,547 | 18,360 | |
| Total Debt | 1,034 | 1,528 | 1,575 |
Amplia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Amplia Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Amplia Therapeutics Patents
Amplia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023900354-A0 | Combination therapy | Inactive | 14-Feb-2023 | ||
| AU-2020901743-A0 | Methods of treating pulmonary fibrosis | Inactive | 28-May-2020 | ||
| AU-2021279205-A1 | Methods of treating pulmonary fibrosis | Pending | 28-May-2020 | ||
| EP-4157278-A1 | Methods of treating pulmonary fibrosis | Pending | 28-May-2020 | ||
| CA-3177652-A1 | Methods of treating pulmonary fibrosis | Pending | 28-May-2020 | A61K31/506 |
Amplia Therapeutics Executive Team (7)
| Name | Title | Board Seat |
|---|---|---|
| Christopher Burns Ph.D | Chief Executive Officer, Managing Director & Non-Executive Director | |
| Tim Luscombe | Chief Financial Officer | |
| Rhiannon Jones Ph.D | Chief Operating Officer | |
| Mark Devlin Ph.D | Scientific Adviser |
Amplia Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Amplia Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Amplia Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Amplia Therapeutics (North Melbourne) | 04-May-2018 | Pharmaceuticals |
Amplia Therapeutics FAQs
-
When was Amplia Therapeutics founded?
Amplia Therapeutics was founded in 2000.
-
Who is the CEO of Amplia Therapeutics?
Christopher Burns Ph.D is the CEO of Amplia Therapeutics.
-
Where is Amplia Therapeutics headquartered?
Amplia Therapeutics is headquartered in Melbourne, Australia.
-
What is the size of Amplia Therapeutics?
Amplia Therapeutics has 9 total employees.
-
What industry is Amplia Therapeutics in?
Amplia Therapeutics’s primary industry is Biotechnology.
-
Is Amplia Therapeutics a private or public company?
Amplia Therapeutics is a Public company.
-
What is Amplia Therapeutics’s stock symbol?
The ticker symbol for Amplia Therapeutics is ATX.
-
What is the current stock price of Amplia Therapeutics?
As of 11-Oct-2024 the stock price of Amplia Therapeutics is $0.11.
-
What is the current market cap of Amplia Therapeutics?
The current market capitalization of Amplia Therapeutics is $30.5M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
